Global Drug Addiction Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Drug Addiction treatment during 2019. Clinical development activities are being undertaken by more than 40 companies including Addex Therapeutics Ltd, Aelis Farma SAS, Amygdala Neurosciences Inc, Aphios Corp, Astraea Therapeutics LLC and others.
A Significant contribution to the Drug Addiction pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Drug Addiction pipeline included 40 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Drug Addiction condition and increased access to investments is encouraging growth of Drug Addiction drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Drug Addiction drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Drug Addiction therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Drug Addiction pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Drug Addiction. Further, orphan drug status, fast track designation, grants awarded and other special status for Drug Addiction pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Drug Addiction pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Drug Addiction Pipeline candidates-
A Significant contribution to the Drug Addiction pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Drug Addiction pipeline included 40 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Drug Addiction condition and increased access to investments is encouraging growth of Drug Addiction drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Drug Addiction drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Drug Addiction therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Drug Addiction pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Drug Addiction. Further, orphan drug status, fast track designation, grants awarded and other special status for Drug Addiction pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Drug Addiction pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Drug Addiction Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Drug Addiction drugs
- Late phase: Phase 3 and in-approval Drug Addiction drugs
- Company overview
- Snapshot
- Drug Addiction therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Drug Addiction- Disease Overview
2.2 Drug Addiction- Pipeline Snapshot
2.3 Drug Addiction- Pipeline Drugs by Phase
2.4 Drug Addiction- Pipeline Drugs by Company
2.5 Drug Addiction- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Addex Therapeutics Ltd Drug Addiction Drug Pipeline, H2- 2019
3.2 Aelis Farma SAS Drug Addiction Drug Pipeline, H2- 2019
3.3 Amygdala Neurosciences Inc Drug Addiction Drug Pipeline, H2- 2019
3.4 Aphios Corp Drug Addiction Drug Pipeline, H2- 2019
3.5 Astraea Therapeutics LLC Drug Addiction Drug Pipeline, H2- 2019
3.6 BioCorRx Inc Drug Addiction Drug Pipeline, H2- 2019
3.7 Camino Pharma LLC Drug Addiction Drug Pipeline, H2- 2019
3.8 Charleston Laboratories Inc Drug Addiction Drug Pipeline, H2- 2019
3.9 Chiesi Farmaceutici SpA Drug Addiction Drug Pipeline, H2- 2019
3.10 Consegna Pharma Inc Drug Addiction Drug Pipeline, H2- 2019
3.11 Curemark LLC Drug Addiction Drug Pipeline, H2- 2019
3.12 Daya Drug Discoveries Inc Drug Addiction Drug Pipeline, H2- 2019
3.13 Denovo Biopharma LLC Drug Addiction Drug Pipeline, H2- 2019
3.14 Embera NeuroTherapeutics Inc Drug Addiction Drug Pipeline, H2- 2019
3.15 EncepHeal Therapeutics Inc Drug Addiction Drug Pipeline, H2- 2019
3.16 Eolas Therapeutics Inc Drug Addiction Drug Pipeline, H2- 2019
3.17 F. Hoffmann-La Roche Ltd Drug Addiction Drug Pipeline, H2- 2019
3.18 Foresee Pharmaceuticals Co Ltd Drug Addiction Drug Pipeline, H2- 2019
3.19 IMV Inc Drug Addiction Drug Pipeline, H2- 2019
3.20 InterveXion Therapeutics LLC Drug Addiction Drug Pipeline, H2- 2019
3.21 Intra-Cellular Therapies Inc Drug Addiction Drug Pipeline, H2- 2019
3.22 Kdac Therapeutics Inc Drug Addiction Drug Pipeline, H2- 2019
3.23 KemPharm Inc Drug Addiction Drug Pipeline, H2- 2019
3.24 Kinoxis Therapeutics Pty Ltd Drug Addiction Drug Pipeline, H2- 2019
3.25 Kyorin Pharmaceutical Co Ltd Drug Addiction Drug Pipeline, H2- 2019
3.26 Kyowa Hakko Kirin Co Ltd Drug Addiction Drug Pipeline, H2- 2019
3.27 MAKScientific LLC Drug Addiction Drug Pipeline, H2- 2019
3.28 Mayo Clinic Drug Addiction Drug Pipeline, H2- 2019
3.29 MElkin Pharmaceuticals Drug Addiction Drug Pipeline, H2- 2019
3.30 NLS Pharma Group Drug Addiction Drug Pipeline, H2- 2019
3.31 Omeros Corp Drug Addiction Drug Pipeline, H2- 2019
3.32 Orexigen Therapeutics Inc Drug Addiction Drug Pipeline, H2- 2019
3.33 P2D Inc Drug Addiction Drug Pipeline, H2- 2019
3.34 Protagenic Therapeutics Inc Drug Addiction Drug Pipeline, H2- 2019
3.35 Saniona AB Drug Addiction Drug Pipeline, H2- 2019
3.36 Savant HWP Inc Drug Addiction Drug Pipeline, H2- 2019
3.37 Seropeutics LLC Drug Addiction Drug Pipeline, H2- 2019
3.38 Sosei Heptares Drug Addiction Drug Pipeline, H2- 2019
3.39 SpringWorks Therapeutics LLC Drug Addiction Drug Pipeline, H2- 2019
3.40 Zynerba Pharmaceuticals Inc Drug Addiction Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Drug Addiction- Phase 1 Drug Details
4.2 Drug Addiction- Phase 1 Drug Overview
4.3 Drug Addiction- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Drug Addiction- Phase 2 Drug Details
5.2 Drug Addiction- Phase 2 Drug Overview
5.3 Drug Addiction- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Drug Addiction- Phase 3 Drug Details
6.2 Drug Addiction- Phase 3 Drug Overview
6.3 Drug Addiction- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Drug Addiction- Pre-clinical Phase Drug Details
7.2 Drug Addiction- Pre-clinical Phase Drug Overview
7.3 Drug Addiction- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Drug Addiction- Disease Overview
2.2 Drug Addiction- Pipeline Snapshot
2.3 Drug Addiction- Pipeline Drugs by Phase
2.4 Drug Addiction- Pipeline Drugs by Company
2.5 Drug Addiction- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Addex Therapeutics Ltd Drug Addiction Drug Pipeline, H2- 2019
3.2 Aelis Farma SAS Drug Addiction Drug Pipeline, H2- 2019
3.3 Amygdala Neurosciences Inc Drug Addiction Drug Pipeline, H2- 2019
3.4 Aphios Corp Drug Addiction Drug Pipeline, H2- 2019
3.5 Astraea Therapeutics LLC Drug Addiction Drug Pipeline, H2- 2019
3.6 BioCorRx Inc Drug Addiction Drug Pipeline, H2- 2019
3.7 Camino Pharma LLC Drug Addiction Drug Pipeline, H2- 2019
3.8 Charleston Laboratories Inc Drug Addiction Drug Pipeline, H2- 2019
3.9 Chiesi Farmaceutici SpA Drug Addiction Drug Pipeline, H2- 2019
3.10 Consegna Pharma Inc Drug Addiction Drug Pipeline, H2- 2019
3.11 Curemark LLC Drug Addiction Drug Pipeline, H2- 2019
3.12 Daya Drug Discoveries Inc Drug Addiction Drug Pipeline, H2- 2019
3.13 Denovo Biopharma LLC Drug Addiction Drug Pipeline, H2- 2019
3.14 Embera NeuroTherapeutics Inc Drug Addiction Drug Pipeline, H2- 2019
3.15 EncepHeal Therapeutics Inc Drug Addiction Drug Pipeline, H2- 2019
3.16 Eolas Therapeutics Inc Drug Addiction Drug Pipeline, H2- 2019
3.17 F. Hoffmann-La Roche Ltd Drug Addiction Drug Pipeline, H2- 2019
3.18 Foresee Pharmaceuticals Co Ltd Drug Addiction Drug Pipeline, H2- 2019
3.19 IMV Inc Drug Addiction Drug Pipeline, H2- 2019
3.20 InterveXion Therapeutics LLC Drug Addiction Drug Pipeline, H2- 2019
3.21 Intra-Cellular Therapies Inc Drug Addiction Drug Pipeline, H2- 2019
3.22 Kdac Therapeutics Inc Drug Addiction Drug Pipeline, H2- 2019
3.23 KemPharm Inc Drug Addiction Drug Pipeline, H2- 2019
3.24 Kinoxis Therapeutics Pty Ltd Drug Addiction Drug Pipeline, H2- 2019
3.25 Kyorin Pharmaceutical Co Ltd Drug Addiction Drug Pipeline, H2- 2019
3.26 Kyowa Hakko Kirin Co Ltd Drug Addiction Drug Pipeline, H2- 2019
3.27 MAKScientific LLC Drug Addiction Drug Pipeline, H2- 2019
3.28 Mayo Clinic Drug Addiction Drug Pipeline, H2- 2019
3.29 MElkin Pharmaceuticals Drug Addiction Drug Pipeline, H2- 2019
3.30 NLS Pharma Group Drug Addiction Drug Pipeline, H2- 2019
3.31 Omeros Corp Drug Addiction Drug Pipeline, H2- 2019
3.32 Orexigen Therapeutics Inc Drug Addiction Drug Pipeline, H2- 2019
3.33 P2D Inc Drug Addiction Drug Pipeline, H2- 2019
3.34 Protagenic Therapeutics Inc Drug Addiction Drug Pipeline, H2- 2019
3.35 Saniona AB Drug Addiction Drug Pipeline, H2- 2019
3.36 Savant HWP Inc Drug Addiction Drug Pipeline, H2- 2019
3.37 Seropeutics LLC Drug Addiction Drug Pipeline, H2- 2019
3.38 Sosei Heptares Drug Addiction Drug Pipeline, H2- 2019
3.39 SpringWorks Therapeutics LLC Drug Addiction Drug Pipeline, H2- 2019
3.40 Zynerba Pharmaceuticals Inc Drug Addiction Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Drug Addiction- Phase 1 Drug Details
4.2 Drug Addiction- Phase 1 Drug Overview
4.3 Drug Addiction- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Drug Addiction- Phase 2 Drug Details
5.2 Drug Addiction- Phase 2 Drug Overview
5.3 Drug Addiction- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Drug Addiction- Phase 3 Drug Details
6.2 Drug Addiction- Phase 3 Drug Overview
6.3 Drug Addiction- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Drug Addiction- Pre-clinical Phase Drug Details
7.2 Drug Addiction- Pre-clinical Phase Drug Overview
7.3 Drug Addiction- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
